Skip to main content
. 2011 Jun 24;1(6):e26. doi: 10.1038/bcj.2011.24

Figure 4.

Figure 4

AMD3100 treatment, downmodulates CXCR4, activates miR-146a and impairs leukemic cell proliferation. (a) Growth curve of U937-miR146a (miR-146a) and control U937-Empty (E) cells treated with AMD3100 added every two days in cultures, compared with untreated cells. (b) Quantitative real-time PCR analysis of CXCR4 mRNA and (c) miR-146a expression were, respectively, performed on the indicated days, in U937-miR146a cells as compared with control cells (wt and E), treated by AMD3100 compared with untreated cells (day 0). (d) FACS analysis of CXCR4 protein expression at sequential days during AMD3100 treatment of U937-miR146a and control cells (wt and E) compared with untreated cells (day 0). CXCR4 protein expression was evaluated at both, total (left panel) and membrane (right panel) level, on permeabilized or intact cells, respectively. The geometric MFI is shown as mean±s.e.m. values from three independent experiments. (e) FACS analysis of total and membrane CXCR4 protein expression, as compared with (f) internalized CXCR4 protein levels during acute (1 and 4 h) AMD3100 treatment of U937-miR146a and control wt and E cells. (a) One representative experiment out of three is shown. (b–f) Results of three independent experiments are shown (mean±s.e.m. values).